74825-1 |
Saint Louis encephalitis virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Saint Louis encephalitis virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74825-1 |
|
HAI |
|
|
Both |
|
|
|
0 |
SLEV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Enc; Enceph; Encephalomyelitis; Hemagglutination inhibition; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SLE virus; SLEV; SR; St Louis |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74826-9 |
Semliki forest virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Semliki Forest virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74826-9 |
|
HAI |
|
|
Both |
|
|
|
0 |
SFV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Alphaviruses; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Hemagglutination inhibition; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SFV; SR |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74827-7 |
Snowshoe hare virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Snowshoe hare virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74827-7 |
|
HAI |
|
|
Both |
|
|
|
0 |
SSHV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Hemagglutination inhibition; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SSHV |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74828-5 |
Snowshoe hare virus Ab.Neut |
PrThr |
Ser |
Pt |
Ord |
Neut |
|
ACTIVE |
Snowshoe hare virus neutralizing antibody [Presence] in Serum by Neutralization test |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74828-5 |
|
Neut |
|
|
Both |
|
|
|
0 |
SSHV NAb Ser Ql Nt |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Conventional virus neutralization test; cVNT; ID; Infectious Disease; InfectiousDisease; Microbiology; NAb; NEUTRALIZATION; Neutralization test; NT; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; Serum virus neutralization; SR; SSHV; SVN; Virus neutralization test; VNT |
2.72 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: COMPONENT: Updated "Ab" to "Ab.Neut" since this test is detecting neutralizing antibodies.; Previous Releases: The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74829-3 |
Snowshoe hare virus Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Snowshoe hare virus IgG Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74829-3 |
|
IF |
|
|
Both |
|
|
|
0 |
SSHV IgG Ser Ql IF |
|
|
|
|
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SSHV; Time Resolved Fluorescence; TRF |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
7483-1 |
Maple syrup Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Maple syrup IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
7483-1 |
|
|
|
|
Both |
|
|
|
0 |
Maple Syrup IgE Qn |
|
|
|
Y |
|
ABS; Aby; Acer; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; f377; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
74830-1 |
Toxoplasma gondii Ab.IgA |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Toxoplasma gondii IgA Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74830-1 |
|
IA |
|
|
Both |
|
|
|
0 |
T gondii IgA Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin A; Immunoglobulin A; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; T gondii; Toxo; Toxoplasmosis |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
74831-9 |
Metanephrine & Normetanephrine panel |
SCnc |
Urine |
Pt |
- |
|
|
DEPRECATED |
Deprecated Metanephrine and Normetanephrine panel [Moles/volume] - Urine |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
74831-9 |
|
|
|
|
Order |
|
|
|
0 |
Deprecated Metaneph+Normetaneph Pnl Ur-sCnc |
|
|
|
|
|
Chemistry; Level; Metaneph; Metaneph+Normetaneph; Metaneph+Normetaneph Pnl; Metanephrine fractionated; Metanephrines panel; Metanephrne; Metenephrine; Normeta; Normetaneph; Normetanephrn; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; Substance concentration; UA; UR; Urn |
2.63 |
2.48 |
|
Panel |
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
74832-7 |
OLANZapine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
OLANZapine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
mg |
|
|
|
|
|
|
DRUGDOSE |
|
74832-7 |
|
|
|
|
Observation |
|
|
|
0 |
OLANZapine Dose |
|
|
|
|
|
Dose med or substance; DRUG DOSES; Lanzek; Point in time; QNT; Quan; Quant; Quantitative; Random; Zypadhera; Zyprexa |
2.56 |
2.48 |
|
|
|
|
|
|
|
mg |
|
|
Changed Order_obs from 'Both" to fit the current LOINC model. |
0 |
74833-5 |
ACAT1 gene full mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Sequencing |
|
ACTIVE |
ACAT1 gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
74833-5 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
ACAT1 Full Mut Anl Bld/T Seq |
|
|
|
|
|
ACAT; acetyl-CoA acetyltransferase 1; Blood; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Identity or presence; Inherited; MAT; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mutations; Next generation sequencing; NGS; Nominal; Point in time; Random; sequencing of entire coding region; T2; THIL; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.67 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.67: SYSTEM: Updated System from "Bld/Tiss/Sal" to "Bld/Tiss" since this System in LOINC encompasses all specimens used for germline nucleic acid testing, including blood, tissue and cells contained in swabs as well as fluids such as saliva. |
0 |
74834-3 |
MARS2 gene full mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Sequencing |
|
ACTIVE |
MARS2 gene mutations found [Identifier] in Blood or Tissue by Sequencing Nominal |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
74834-3 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
MARS2 Full Mut Anl Bld/T Seq |
|
|
|
|
|
Blood; full gene sequencing; Full Mut Anl; Genetics; Heredity; Heritable; high-throughput sequencing; HTS; Identity or presence; Inherited; MARS2 full mut analysis; methionyl-tRNA synthetase 2, mitochondrial; MetRS; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; mtMetRS; Mut; Mutations; Next generation sequencing; NGS; Nominal; Point in time; Random; sequencing of entire coding region; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.67 |
2.48 |
|
|
|
|
|
|
|
|
|
|
Release 2.67: SYSTEM: Updated System from "Bld/Tiss/Sal" to "Bld/Tiss" since this System in LOINC encompasses all specimens used for germline nucleic acid testing, including blood, tissue and cells contained in swabs as well as fluids such as saliva. |
0 |
74835-0 |
Porphyrin fractions panel |
SFr |
Stool |
Pt |
- |
|
|
ACTIVE |
Porphyrin fractions panel - Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
74835-0 |
|
|
|
|
Order |
|
|
|
0 |
Porphyrin Fract Pnl SFr Stl |
|
|
|
|
|
Bowel movement; Chemistry; Faecal; Faeces; Fecal; Feces; Frac; Fract; Fraction; Fractionated; Fractionation; Pan; PANEL.CHEMISTRY; Panl; Percent; Pnl; Point in time; Porphyrin Fract Pnl; Random; Stl; Stool = Fecal; Substance Fraction |
2.48 |
2.48 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
74836-8 |
Transplant type |
Anat |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Transplant type [Anatomy] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CLIN |
|
74836-8 |
|
|
|
|
Observation |
|
|
|
0 |
Trns Typ |
|
|
|
|
|
Anatomy; CLIN; Nominal; Point in time; Random; Trns Typ |
2.48 |
2.48 |
|
|
|
|
|
|
|
|
|
|
|
0 |
74837-6 |
Cells.CD20 |
NCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD20 cells [#/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
10*6/L |
|
|
|
|
|
|
CELLMARK |
|
74837-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD20 Cells # Spec |
|
|
|
|
|
#; ABS; absolute; absolutes; B1; B-1; Bp35; CD20 Cells; Cell; CELL MARKERS; Cells.CD20+; Cellularity; Cnt; Count; Count/volume; CT; Leu16; Leu-16; Misc; Miscellaneous; Number concentration; Number Concentration (count/vol); Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.48 |
|
|
|
|
|
|
|
10*6/L |
|
|
|
0 |
74838-4 |
Cells.CD34 |
NCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD34 cells [#/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
10*6/L |
|
|
|
|
|
|
CELLMARK |
|
74838-4 |
|
|
|
|
Observation |
|
|
|
0 |
CD34 Cells # Spec |
|
|
|
|
|
#; ABS; absolute; absolutes; CD34 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; gp105-120; Hematopoietic stem cell; HSC; Misc; Miscellaneous; My10; My-10; Number concentration; Number Concentration (count/vol); Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Stem cells; To be specified in another part of the message; Unspecified |
2.69 |
2.48 |
|
|
|
|
|
|
|
10*6/L |
|
|
|
0 |
74839-2 |
Cells.CD3-CD4+/Cells |
NFr |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD3-CD4+ cells/cells in Specimen |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
74839-2 |
|
|
|
|
Observation |
|
|
|
0 |
CD3-CD4+ NFr Spec |
|
|
|
|
|
CD3 Cells; CD3+CD4+ Cells; CD4+ T cells; Cell; CELL MARKERS; Cellularity; Helper T cells; Inducer T cells; L3T4; Leu3; Leu-3; Leu4; Leu-4; Misc; Miscellaneous; Number fraction; Other; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; T3; T4; T-4; T4 helper/inducer cells; To be specified in another part of the message; Unspecified; W3/25 |
2.79 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
7484-9 |
Iva xanthifolia Ab.IgE |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Burweed marshelder IgE Ab [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
kIU/L |
|
|
|
|
|
|
ALLERGY |
|
7484-9 |
|
|
|
|
Both |
|
|
|
0 |
Burweed marshelder IgE Qn |
|
|
|
Y |
|
ABS; Aby; Allergen; Allergens; ALLERGY TESTING; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Burweed Marsh elder; Burweed marshelder; Immune globulin E; Immunoglobulin E; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
k[IU]/L |
|
|
|
0 |
74840-0 |
Cells.CD56 |
NCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD56 cells [#/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
10*6/L |
|
|
|
|
|
|
CELLMARK |
|
74840-0 |
|
|
|
|
Observation |
|
|
|
0 |
CD56 Cells # Spec |
|
|
|
|
|
#; ABS; absolute; absolutes; CD56 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; Leu19; Leu-19; Misc; Miscellaneous; NCAM; Neural cell adhesion molecule; NKH1; Number concentration; Number Concentration (count/vol); Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.69 |
2.48 |
|
|
|
|
|
|
|
10*6/L |
|
|
|
0 |
74841-8 |
Cells.CD8+CD57+/Cells |
NFr |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD8+CD57+ cells/cells in Specimen |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
74841-8 |
|
|
|
|
Observation |
|
|
|
0 |
CD8+CD57+ Cells NFr Spec |
|
|
|
|
|
CD8 Cells; CD8+CD57+ Cells; CD8-CD57+ Cells; Cell; CELL MARKERS; Cellularity; HNK1; Leu2; Leu-2; Leu7; Leu-7; Lyme disease; Misc; Miscellaneous; Natural killer cells; Number fraction; Other; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Suppressor T cells; T8; T-8; To be specified in another part of the message; Tsuppressor; Unspecified |
2.79 |
2.48 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
74842-6 |
Cells.CD25 |
NCnc |
XXX |
Pt |
Qn |
|
|
ACTIVE |
CD25 cells [#/volume] in Specimen |
|
MIN |
DefinitionDescription |
|
|
10*6/L |
|
|
|
|
|
|
CELLMARK |
|
74842-6 |
|
|
|
|
Observation |
|
|
|
0 |
CD25 Cells # Spec |
|
|
|
|
|
#; ABS; absolute; absolutes; CD25 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; IL-2 receptor alpha chain; IL-2R; IL-2R Tac antigen; ILR2; Misc; Miscellaneous; Number concentration; Number Concentration (count/vol); Other; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Tac antigen; To be specified in another part of the message; Unspecified |
2.69 |
2.48 |
|
|
|
|
|
|
|
10*6/L |
|
|
|
0 |
74843-4 |
Baylisascaris sp Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
IA |
|
ACTIVE |
Baylisascaris sp IgG Ab [Presence] in Cerebral spinal fluid by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74843-4 |
|
IA |
|
|
Both |
|
|
|
0 |
Baylis sp IgG CSF Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Baylis sp; Cerebral spinal fluid; Cerebrospinal Fl; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; round worm; Screen; species; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; spp; SUDS |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
74844-2 |
Baylisascaris sp Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Baylisascaris sp IgG Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74844-2 |
|
IA |
|
|
Both |
|
|
|
0 |
Baylis sp IgG Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Baylis sp; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; round worm; Screen; Serum; species; spp; SR; SUDS |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
74845-9 |
Sindbis virus Ab |
PrThr |
Ser |
Pt |
Ord |
HAI |
|
ACTIVE |
Sindbis virus Ab [Presence] in Serum by Hemagglutination inhibition |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74845-9 |
|
HAI |
|
|
Both |
|
|
|
0 |
SINV Ab Ser Ql HAI |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Hemagglutination inhibition; HI; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SINV; SR |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74846-7 |
Snowshoe hare virus Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Snowshoe hare virus IgM Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74846-7 |
|
IF |
|
|
Both |
|
|
|
0 |
SSHV IgM Ser Ql IF |
|
|
|
|
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SSHV; Time Resolved Fluorescence; TRF |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
74847-5 |
Toxoplasma gondii Ab.IgE |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Toxoplasma gondii IgE Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
74847-5 |
|
IA |
|
|
Both |
|
|
|
0 |
T gondii IgE Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Immune globulin E; Immunoglobulin E; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; T gondii; Toxo; Toxoplasmosis |
2.56 |
2.48 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |